Second-line combination therapies in nonsmall cell lung cancer without known driver mutations.

ABSTRACT: In advanced nonsmall cell lung cancer (NSCLC) patients, platinum-based combination chemotherapy is standard treatment in the first-line setting; however, the large majority of patients ultimately progress. For more than a decade, single-agent therapy with docetaxel, pemetrexed or erlotinib has been the standard of care after failure with platinum salts, showing some benefit over best supportive care. Nonetheless, prognosis remains poor and new second-line strategies are urgently needed. Combinations of cytotoxic agents, including rechallenge with platinum salts, do not offer clear benefit over single-agent therapy for the majority of patients. In patients without a known tumoural oncogenic driver mutation, regimens based on combinations of targeted agents have shown promising results; howe

SUBMITTER: Bluthgen MV 

PROVIDER: S-EPMC9487623 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature